Sergei Petukhov

Chief Executive Officer

2024 - Current

Metallomix emerged to revolutionize medicine with our distinctive scientific perspective on disease pathogenesis. Our approach is rooted in over ten years of research that delves deeper than molecular patterns, exploring the isotopic signatures at the atomic level within cells and tissues as part of metalloproteomics.

Founder

2017

Managing Director

2021 - 2024

The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline. The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics.

Board Member

2022 - 2023

World leader in antibacterial & antiviral drug research and development. Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.

Venture Partner

2019 - 2021

Starta Ventures is a seed stage fund with a focus on startups with European R&D roots. Role: Advisory / mentorship Duties: - Advising health-tech companies on development strategies - Providing guidance on clinical path and market fit - Assisting with the accelerator’s capital raise activities - Reporting to LPs, writing the accelerator’s health-tech strategic developmental plan

President

2017 - 2021

Kadem LLC is an advisory firm that provides consultancy services to its clients within biotech and cleantech fields

Vice President Of Business Development

2020 - 2021

Monet Pharmaceuticals has created a novel structural biology Protein Painting Platform (PPP) designed to identify new druggable hot spots in protein-protein (P2P) interactions. PPP is versatile and can be applied to facilitate the discovery of novel biologic therapeutics across a diverse range of disease areas, including oncology, autoimmune and rare diseases. Fundamentally, PPP provides a unique insight into the interactions between protein complexes that fundamentally differs from was previously allowed by the other methods.

Advisor

2018 - 2020

RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally. RBV invests into diversified assets in pharmaceuticals, biologics, digital healthcare products and medical devices answering to an unmet medical and market need and with a potential for global outreach

Board Observer

2016 - 2019

Galera Therapeutics is a clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. Galera Therapeutics is discovering and developing novel mechanism-based therapies that have the potential to improve both treatment and outcomes for patients with cancer.

Director Board Of Directors

2016 - 2019

Cavion, Inc., a precision medicine biotechnology company developing first-in-class therapies to restore the brain's natural rhythms by modulating overactive T-type calcium channels. Cavion's mission is to combine a deep understanding of T-type calcium channel (Cav3) biology with superior chemistry and clinical research innovation and expertise to provide therapeutics that will improve people's lives